<DOC>
	<DOCNO>NCT02759861</DOCNO>
	<brief_summary>To determine efficacy safety Harvoni treatment-naïve alcoholic subject Genotype 1 HCV infection</brief_summary>
	<brief_title>Determine Efficacy Safety Harvoni Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>1 . The subject must willingly able provide write informed consent 2 . Age 19 year age older ( The age consent Nebraska ) 3 . HCV treatmentnaïve , define prior exposure Interferon ( IFN ) , RBV , FDA approve experimental HCVspecific directacting antiviral agent 4 . HCV genotype 1a , 1b , mix 1a/1b screen . Any nondefinitive result exclude subject study participation . HCV RNA level 6 month prior Baseline/Day 1 visit . 5 . Confirmation chronic HCV infection document HCV genotyping test ( do time point ) . 6 . Alcohol misuse define Alcohol Use Disorders Identification Test ( AUDIT ) score subject must score &gt; 8 ( associate harmful hazardous drinking ) 7 . Cirrhosis determination [ 20 % study subject may cirrhosis ] : 1 . Cirrhosis define one following : History liver biopsy show cirrhosis ( e.g . Metavir score = 4 Ishak score &gt; 5 ) Fibroscan show cirrhosis result &gt; 12.5 kPa FibroTest® score &gt; 0.75 AND AST : platelet ratio index ( APRI ) &gt; 2 Screening 2 . Absence cirrhosis define one following : Liver biopsy within 2 year Screening show absence cirrhosis Fibroscan within 6 month Baseline/Day1 result ≤ 12.5 kPa FibroTest® score ≤ 0.48 AND APRI ≤ 1 Screening 8 . Liver image within 6 month Baseline/Day 1 exclude hepatocellular carcinoma HCC ) require 9 . Subjects must follow laboratory parameter screen : 1 . ALT &lt; 10 x upper limit normal ( ULN ) 2 . AST &lt; 10 x ULN 3 . Direct bilirubin &lt; 2.0 x ULN 4 . Platelets &gt; 50,000 5 . HbA1c &lt; 8.5 % 6 . Creatinine clearance ( CLcr ) ≥ 60 mL /min , calculate CockcroftGault equation 7 . Hemoglobin ≥ 11 g/dL female subject ; ≥ 12 g/dL male subject . 8 . Albumin ≥ 2.5 g/dL 9 . INR ≤ 1.5 x ULN unless subject know hemophilia stable anticoagulant regimen affect INR . 10 . Subject treated investigational drug device within 30 day screen visit . 1 . Pregnant woman nurse mother ineligible due possible risk adverse effect newborn . Eligible patient reproductive potential use adequate contraception sexually active . 2 . Serious concurrent medical illness would jeopardize ability subject receive therapy outline protocol reasonable safety . 3 . Malignancy diagnose treat within 5 year ( recent localize treatment squamous noninvasive basal cell skin cancer permit ; cervical carcinoma situ allow appropriately treat prior screen ) ; subject evaluation malignancy eligible . 4 . Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) 5 . Use prohibit concomitant medication within 30 day Baseline/Day 1 visit . 6 . Known hypersensitivity LDV/SOF</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>